He can simply take all pharma manufacturer portfolio off the medicare schedule, for example. That's what I would do, and it would be the right lawful move.
On the side, he may open the door for generic substitutes as well from CAN etc.
A simple price directive would be set at the same time, without any negotiation:
The price US medicare will pay will only be the average price for each drug, in all OECD countries.